Skip to content

Long-Term Evaluation of TAILORED Vs Anatomical Ablation Strategy for Persistent Atrial Fibrillation

Long-Term Evaluation of TAILORED Vs Anatomical Ablation Strategy for Persistent Atrial Fibrillation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06825104
Acronym
TAILORED-LT
Enrollment
278
Registered
2025-02-13
Start date
2025-03-06
Completion date
2027-12-31
Last updated
2025-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Artificial Intelligence, VX1, Volta AF-Xplorer, Medical Device, Cardiac Dispersion, Volta Medical, Software

Brief summary

The TAILORED-LT study is conducted as an extension follow-up until 5 years of the initial TAILORED-AF study (NCT04702451), in order to demonstrate the long-term superiority in terms of freedom of atrial fibrillation (AF) of a tailored ablation strategy targeting areas of spatio-temporal dispersed electrograms in combination with pulmonary veins isolation (PVI) over an anatomical ablation strategy targeting PVI alone for the initial ablation procedure of persistent AF.

Detailed description

The TAILORED-AF study demonstrated at one year's follow-up that a tailored ablation strategy guided by Volta Medical AI-software targeting areas of spatio-temporal dispersed electrograms in combination with pulmonary vein isolation (PVI) ablation is more effective to an anatomical ablation strategy targeting PVI alone (current standard of care) for the treatment of persistent atrial fibrillation (AF). VX1 legacy device renamed Volta AF-Xplorer was used in the TAILORED-AF study in the treatment arm. No additional treatments are specifically required in the scope of this ancillary TAILORED-LT study which aims to follow the patients previously treated in the initial TAILORED-AF study over the long-term. However, in the event of repeat procedures during the TAILORED-LT study, the choice of the ablation technique will be left to the investigator's discretion, regardless of the patient's randomization arm in the TAILORED-AF study. The annual follow-up will be performed as in routine clinical practice post AF ablation procedures: visits at 24 months, 36 months, 48 months and 60 months post TAILORED-AF Study index procedure. It is possible that some of these annual visits cannot be completed prospectively due to time already having elapsed between the end of the subject participation in the TAILORED-AF study and the date of enrollment in the extension TAILORED-LT study. In this case, available data (among those expected by the study protocol) will be collected retrospectively. The additional procedures related to this clinical investigation are limited to annual 24-hour Holters and to the administration of Quality Of Life questionnaires (SF-36 and AFEQT) to the patients during follow-up visits.

Interventions

DEVICEVolta AF-Xplorer

Dispersion ablation strategy guided by Volta Medical AI-software targeting areas of spatiotemporal dispersed electrograms

TAILORED-AF index procedure: Dispersion ablation + PVI

PROCEDUREPVI

TAILORED-AF index procedure: PVI only

Sponsors

Volta Medical
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient who participated in the Tailored AF study * Patient not withdrawn during the 12-month follow-up period post-index procedure in the Tailored AF study * Patient able and willing to provide written informed consent to participate in this extension Tailored-LT study

Exclusion criteria

* Person deprived of liberty or under guardianship * Person unable to undergo a medical monitoring for geographical, social or psychological reasons

Design outcomes

Primary

MeasureTime frameDescription
Long-term freedom from documented atrial fibrillation (AF) after one ablation procedure60 monthsLong-term freedom from documented AF episodes \> 30 seconds, with or without antiarrhythmic drugs (AADs), after a single index ablation procedure.

Secondary

MeasureTime frameDescription
Long-term freedom from documented AF/AT after one ablation procedure60 monthsLong-term freedom from documented AF/AT episodes \> 30 seconds, after one procedure, with or without AADs
Heath Economics - Average Number of Ablation Procedures per patient60 monthsTo determine how the number of repeat ablation procedures in addition to the index procedure impacts health care costs.
Heath Economics - Average Number of Hospitalizations per patient60 monthsTo determine how the number of hospitalizations post-ablation index procedure impacts health care costs.
Heath Economics - Average Number of Cardioversions per patient60 monthsTo determine how the number of cardioversions post-ablation index procedure affects health care costs.
Long-term freedom from documented AF/AT after one or two ablation procedures60 monthsLong-term freedom from documented AF and Atrial Tachycardia (AT) episodes \> 30 seconds, after one or two procedures, with or without AADs
Heath Economics - Quality of Life Progression (SF-36 Score)60 monthsTo determine how the Quality of life progression after the ablation index procedure (measured with the 36-Item Short Form Health Survey SF-36) impacts health care costs. The SF-36 consists of eight domains measuring physical and mental health, with scores ranging from 0 to 100 (higher scores indicate better quality of life).
Heath Economics - Proportion of Patients Under AAD60 monthsTo determine how the proportion of patients under antiarrhythmic drugs (AAD) impacts health care costs.
Incidence of complications (safety composite endpoint)60 monthsIncidence of complications: death, cerebrovascular events, or serious treatment-related adverse event at long-term. NOTE: In addition, each component of the composite endpoint will be individually assessed.
Heath Economics - Quality of Life Progression (AFEQT Score)60 monthsTo determine how the quality of life progression after the ablation index procedure (measured with the Atrial Fibrillation Effect on Quality of Life Questionnaire AFEQT) impacts health care costs. AFEQT score ranges from 0 to 100, with higher scores indicating better quality of life.

Countries

France, Germany

Contacts

Primary ContactPaola MILPIED
paola.milpied@volta-medical.com(0)768025499
Backup ContactCecile BIELMANN
cecile.bielmann@volta-medical.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026